Company Profile

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE1364.20-2 (-0.15 % )
PREV CLOSE (Rs.) 1366.20
OPEN PRICE (Rs.) 1369.45
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1282
TODAY'S LOW / HIGH (Rs.)1300.00 1390.00
52 WK LOW / HIGH (Rs.)840 1543.7
NSE1366.05 -0.25 (-0.02 % )
PREV CLOSE(Rs.) 1366.30
OPEN PRICE (Rs.) 1380.00
BID PRICE (QTY) 1366.05 (10 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 42023
TODAY'S LOW / HIGH(Rs.) 1331.00 1384.95
52 WK LOW / HIGH (Rs.)825 1545

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.66
TTM EPS (Rs.) 45.15
P/E Ratio 30.21
Book Value (Rs.) 285.30
Face Value (Rs.) 2
MCap (Rs. in Mn) 119041.82
Price/Earning (TTM) 24.87
Price/Sales (TTM) 5.81
Price/Book (MRQ) 4.78
PAT Margin (%) 22.10
ROCE (%) 25.21
Incorporation Year : 1979

Management Info :

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office :

Address : Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone : 91-22-66061000

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
21Jan01-21-2020$Ajanta Pharma informs about newspaper publication Ajanta Pharma informs about

Pursuant to Regulation 47 of the Listing Regulations, Ajanta Pharma has informed that the meeting of Board of Directors of the Company to be held on Wednesday, 5th February 2020 published in the newspapers, The Free Press Journal (Mumbai edition) and Navshakti (Mumbai edition) on 21st January 2020.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 47 of the Listing Regulations, Ajanta Ph..
20Jan01-20-2020$ Board Meeting Intimation for Board Meeting Intimation For Quarterly Results. Board Meeting Intimation fo
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Listing Regulations, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Wednesday, 5th February 2020 in Mumbai to inter-alia consider and approve unaudited consolidated and standalone financial results of the Company for the third quarter ended 3lst December 2019. Kindly take note of the same and inform your members suitably.
AJANTA PHARMA LTD.has informed BSE that the meeting of the Boar..
06Nov11-06-2019$Ajanta Pharma reports 7% fall in Q2 consolidated net profit Ajanta Pharma reports 7% fal

Ajanta Pharma has reported results for second quarter ended September 30, 2019.

The company has reported a rise of 15.95% in its net profit at Rs 120.70 crore for the quarter under review as compared to Rs 104.10 crore for the same quarter in the previous year. Total income of the company increased by 24.17% at Rs 598.76 crore for Q2FY20 as compared Rs 482.22 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 7.20% in its net profit at Rs 116.36 crore for the quarter under review as compared to Rs 125.39 crore for the same quarter in the previous year. However, total income of the company increased by 17.28% at Rs 655.98 crore for Q2FY20 as compared Rs 559.35 crore for the corresponding quarter previous year.

Ajanta Pharma has reported results for second quarter ended Sep..
06Nov11-06-2019$Ajanta Pharma advances despite reporting 7% fall in Q2 consolidated net profit Ajanta Pharma advances despi

Ajanta Pharma is currently trading at Rs. 1013.85, up by 11.45 points or 1.14% from its previous closing of Rs. 1002.40 on the BSE.

The scrip opened at Rs. 1025.00 and has touched a high and low of Rs. 1033.00 and Rs. 996.15 respectively. So far 16048 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1204.25 on 31-Dec-2018 and a 52 week low of Rs. 840.00 on 31-Jul-2019.

Last one week high and low of the scrip stood at Rs. 1088.00 and Rs. 906.50 respectively. The current market cap of the company is Rs. 8825.60 crore.

The promoters holding in the company stood at 70.51%, while Institutions and Non-Institutions held 20.14% and 9.35% respectively.

Ajanta Pharma has reported a rise of 15.95% in its net profit at Rs 120.70 crore for the quarter ended September 30, 2019 as compared to Rs 104.10 crore for the same quarter in the previous year. Total income of the company increased by 24.17% at Rs 598.76 crore for Q2FY20 as compared Rs 482.22 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 7.20% in its net profit at Rs 116.36 crore for the quarter under review as compared to Rs 125.39 crore for the same quarter in the previous year. However, total income of the company increased by 17.28% at Rs 655.98 crore for Q2FY20 as compared Rs 559.35 crore for the corresponding quarter previous year.

Ajanta Pharma is currently trading at Rs. 1013.85, up by 11.45..
11Oct10-11-2019$Ajanta Pharma informs about company updates Ajanta Pharma informs about

As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ajanta Pharma has confirmed that activities in relation to both physical and electronic share transfer facility are maintained during the period 1st April 2019 to 30th September 2019, by the Company’s Registrar and Share Transfer Agent, Link Intime India, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058. 

The above information is a part of company’s filings submitted to BSE.

As per the requirement of Regulation 7(3) of the SEBI (Listing..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit1083.23917.6
Gross Profit 1657.7 5130.5
Operating Profit 1894.55833.6
Net Sales 5305.517726.2
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 6483.75 (3.87%)
M.Cap ( in Cr)
14932.48
Abbott India (BSE)
 15639.50 (1.19%)
M.Cap ( in Cr)
33232.85
Hester Biosciences (BSE)
 951.70 (2.88%)
M.Cap ( in Cr)
809.60
Procter&Gamble Healt (BSE)
 3669.75 (0.69%)
M.Cap ( in Cr)
6091.56
NGL Fine-Chem (BSE)
 274.45 (8.33%)
M.Cap ( in Cr)
169.56
Shareholding Pattern More
NON-INSTITUTION 9.3 %
PROMOTERS 70.51 %
MUTUAL FUNDS/UTI 10.37 %
GOVERNMENT 0.74 %
FI/BANKS/INSURANCE 0.65 %
FII 0 %
F & O Quotes